Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Biotech & pharma
CHARLOTTETOWN, Prince Edward Island, Sept. 19, 2026 -- Today, MADD Canada will unveil its new Prince Edward Island (PEI) Provincial Memorial Monument, creating a permanent place to remember victims of alcohol- and drug-related crashes. The monument, engraved with the names of 12 victims, is located at Joseph A. Ghiz Memorial Park.
Sep 19 · 10:05·GlobeNewswire
Biotech & pharma
NEW ORLEANS, Sept. 18, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff applications in a securities class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or the...
Sep 19 · 02:00·PR Newswire
Finance · Biotech & pharma
NEW YORK, Sept. 18, 2026 --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
Sep 19 · 01:39·GlobeNewswire
Healthcare · Biotech & pharma
As reports grow of psychotropic drug harms and some psychiatric hospital staff being prosecuted for child sexual abuse, parents need facts to protect their children.
As reports grow of psychotropic drug harms and some psychiatric hospital staff being prosecuted for child sexual abuse, parents need facts to protect their children.
Sep 19 · 01:17·GlobeNewswire
Finance · Biotech & pharma
NEW YORK, Sept. 18, 2026 --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.
Sep 19 · 00:32·GlobeNewswire
Finance · Biotech & pharma
SAN DIEGO, Sept. 18, 2026 -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26,...
Sep 18 · 23:07·PR Newswire
Finance · Biotech & pharma
San Diego, California--(September 18, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until Monday, September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Captioned Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385 (S.D. Cal.), the Capricor class action...
Sep 18 · 21:45·Newsfile
Finance · Biotech & pharma
SAN CARLOS, Calif., Sept. 18, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 179,750 shares of Iovance’s common stock to eighteen new, non-executive employees.
Sep 18 · 21:10·GlobeNewswire
Finance · Healthcare
Vancouver, British Columbia--(September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that the shareholders' equity of $1,075,007 as reported in the...
Sep 18 · 20:45·Newsfile
Finance · Biotech & pharma
PARSIPPANY, N.J., Sept. 18, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older patients (aged ≥55 years). The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
Sep 18 · 20:32·GlobeNewswire
Finance · Healthcare
PARSIPPANY, N.J., Sept. 18, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) treated with UZEDY (risperidone) extended-release injectable suspension. The results demonstrate how UZEDY helps patients with schizophrenia remain on treatment longer while reducing emergency care and healthcare costs compared with other treatment options. The new findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
Sep 18 · 20:31·GlobeNewswire
Finance · Biotech & pharma
PARSIPPANY, N.J., Sept. 18, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-'749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS data highlighted the acute and long-term durability, efficacy and safety of TEV-'749 as a once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults. The findings were presented at Psych Congress, held September 15 – 19, 2026, in New Orleans, LA.
Sep 18 · 20:30·GlobeNewswire